Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaroration with GA2LEN

J. Bousquet, P. Van Cauwenberge, N. Ad'T Khaled, C. Bachert, C. E. Baena-Cagnani, J. Bouchard, C. Bunnag, G. W. Canonica, K. H. Carlsen, Y. -. Z. Chen, A. A. Cruz, A. Custovic, P. Demoly, R. Dubakiene, S. Durham, W. Fokkens, P. Howarth, J. Kemp, M. L. Kowalski, V. Kvedariene & 22 others B. Lipworth, R. Lockey, V. Lund, S. Mavale-Manuel, E. O. Meltzer, J. Mullol, R. Naclerio, K. Nekam, K. Ohta, N. Papadopoulos, G. Passalacqua, R. Pawankar, T. Popov, P. Potter, David Brendan Price, G. Scadding, F. E. R. Simons, V. Spicak, E. Valovirta, D. -. Y. Wang, B. Yawn, O. Yusuf

Research output: Contribution to journalEditorial

105 Citations (Scopus)

Abstract

The pharmacologic treatment of allergic rhinitis proposed by ARIA is an evidence-based and step-wise approach based on the classification of the symptoms. The ARIA workshop, held in December 1999, published a report in 2001 and new information has subsequently been published. The initial ARIA document lacked some important information on several issues. This document updates the ARIA sections on the pharmacologic and anti-IgE treatments of allergic rhinitis. Literature published between January 2000 and December 2004 has been included. Only a few studies assessing nasal and non-nasal symptoms are presented as these will be discussed in a separate document.

Original languageEnglish
Pages (from-to)1086-1096
Number of pages10
JournalAllergy
Volume61
DOIs
Publication statusPublished - Sep 2006

Keywords

  • ARIA
  • asthma
  • GA(2)LEN
  • IgE
  • pharmacotherapy
  • rhinitis
  • AQUEOUS NASAL SPRAY
  • PLACEBO-CONTROLLED TRIAL
  • QUALITY-OF-LIFE
  • LORATADINE 10 MG
  • INTRANASAL FLUTICASONE PROPIONATE
  • ENVIRONMENTAL EXPOSURE UNIT
  • RANDOMIZED CONTROLLED-TRIAL
  • EBASTINE 20 MG
  • LEUKOTRIENE RECEPTOR ANTAGONISTS
  • ADRENAL AXIS FUNCTION

Cite this

Bousquet, J., Van Cauwenberge, P., Ad'T Khaled, N., Bachert, C., Baena-Cagnani, C. E., Bouchard, J., ... Yusuf, O. (2006). Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaroration with GA2LEN. Allergy, 61, 1086-1096. https://doi.org/10.1111/j.1398-9995.2006.01144.x

Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaroration with GA2LEN. / Bousquet, J.; Van Cauwenberge, P.; Ad'T Khaled, N.; Bachert, C.; Baena-Cagnani, C. E.; Bouchard, J.; Bunnag, C.; Canonica, G. W.; Carlsen, K. H.; Chen, Y. -. Z.; Cruz, A. A.; Custovic, A.; Demoly, P.; Dubakiene, R.; Durham, S.; Fokkens, W.; Howarth, P.; Kemp, J.; Kowalski, M. L.; Kvedariene, V.; Lipworth, B.; Lockey, R.; Lund, V.; Mavale-Manuel, S.; Meltzer, E. O.; Mullol, J.; Naclerio, R.; Nekam, K.; Ohta, K.; Papadopoulos, N.; Passalacqua, G.; Pawankar, R.; Popov, T.; Potter, P.; Price, David Brendan; Scadding, G.; Simons, F. E. R.; Spicak, V.; Valovirta, E.; Wang, D. -. Y.; Yawn, B.; Yusuf, O.

In: Allergy, Vol. 61, 09.2006, p. 1086-1096.

Research output: Contribution to journalEditorial

Bousquet, J, Van Cauwenberge, P, Ad'T Khaled, N, Bachert, C, Baena-Cagnani, CE, Bouchard, J, Bunnag, C, Canonica, GW, Carlsen, KH, Chen, YZ, Cruz, AA, Custovic, A, Demoly, P, Dubakiene, R, Durham, S, Fokkens, W, Howarth, P, Kemp, J, Kowalski, ML, Kvedariene, V, Lipworth, B, Lockey, R, Lund, V, Mavale-Manuel, S, Meltzer, EO, Mullol, J, Naclerio, R, Nekam, K, Ohta, K, Papadopoulos, N, Passalacqua, G, Pawankar, R, Popov, T, Potter, P, Price, DB, Scadding, G, Simons, FER, Spicak, V, Valovirta, E, Wang, DY, Yawn, B & Yusuf, O 2006, 'Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaroration with GA2LEN', Allergy, vol. 61, pp. 1086-1096. https://doi.org/10.1111/j.1398-9995.2006.01144.x
Bousquet J, Van Cauwenberge P, Ad'T Khaled N, Bachert C, Baena-Cagnani CE, Bouchard J et al. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaroration with GA2LEN. Allergy. 2006 Sep;61:1086-1096. https://doi.org/10.1111/j.1398-9995.2006.01144.x
Bousquet, J. ; Van Cauwenberge, P. ; Ad'T Khaled, N. ; Bachert, C. ; Baena-Cagnani, C. E. ; Bouchard, J. ; Bunnag, C. ; Canonica, G. W. ; Carlsen, K. H. ; Chen, Y. -. Z. ; Cruz, A. A. ; Custovic, A. ; Demoly, P. ; Dubakiene, R. ; Durham, S. ; Fokkens, W. ; Howarth, P. ; Kemp, J. ; Kowalski, M. L. ; Kvedariene, V. ; Lipworth, B. ; Lockey, R. ; Lund, V. ; Mavale-Manuel, S. ; Meltzer, E. O. ; Mullol, J. ; Naclerio, R. ; Nekam, K. ; Ohta, K. ; Papadopoulos, N. ; Passalacqua, G. ; Pawankar, R. ; Popov, T. ; Potter, P. ; Price, David Brendan ; Scadding, G. ; Simons, F. E. R. ; Spicak, V. ; Valovirta, E. ; Wang, D. -. Y. ; Yawn, B. ; Yusuf, O. / Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaroration with GA2LEN. In: Allergy. 2006 ; Vol. 61. pp. 1086-1096.
@article{7d723b3e78934777ac6c2096601d53be,
title = "Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaroration with GA2LEN",
abstract = "The pharmacologic treatment of allergic rhinitis proposed by ARIA is an evidence-based and step-wise approach based on the classification of the symptoms. The ARIA workshop, held in December 1999, published a report in 2001 and new information has subsequently been published. The initial ARIA document lacked some important information on several issues. This document updates the ARIA sections on the pharmacologic and anti-IgE treatments of allergic rhinitis. Literature published between January 2000 and December 2004 has been included. Only a few studies assessing nasal and non-nasal symptoms are presented as these will be discussed in a separate document.",
keywords = "ARIA, asthma, GA(2)LEN, IgE, pharmacotherapy, rhinitis, AQUEOUS NASAL SPRAY, PLACEBO-CONTROLLED TRIAL, QUALITY-OF-LIFE, LORATADINE 10 MG, INTRANASAL FLUTICASONE PROPIONATE, ENVIRONMENTAL EXPOSURE UNIT, RANDOMIZED CONTROLLED-TRIAL, EBASTINE 20 MG, LEUKOTRIENE RECEPTOR ANTAGONISTS, ADRENAL AXIS FUNCTION",
author = "J. Bousquet and {Van Cauwenberge}, P. and {Ad'T Khaled}, N. and C. Bachert and Baena-Cagnani, {C. E.} and J. Bouchard and C. Bunnag and Canonica, {G. W.} and Carlsen, {K. H.} and Chen, {Y. -. Z.} and Cruz, {A. A.} and A. Custovic and P. Demoly and R. Dubakiene and S. Durham and W. Fokkens and P. Howarth and J. Kemp and Kowalski, {M. L.} and V. Kvedariene and B. Lipworth and R. Lockey and V. Lund and S. Mavale-Manuel and Meltzer, {E. O.} and J. Mullol and R. Naclerio and K. Nekam and K. Ohta and N. Papadopoulos and G. Passalacqua and R. Pawankar and T. Popov and P. Potter and Price, {David Brendan} and G. Scadding and Simons, {F. E. R.} and V. Spicak and E. Valovirta and Wang, {D. -. Y.} and B. Yawn and O. Yusuf",
year = "2006",
month = "9",
doi = "10.1111/j.1398-9995.2006.01144.x",
language = "English",
volume = "61",
pages = "1086--1096",
journal = "Allergy",
issn = "0105-4538",
publisher = "John Wiley & Sons, Ltd (10.1111)",

}

TY - JOUR

T1 - Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaroration with GA2LEN

AU - Bousquet, J.

AU - Van Cauwenberge, P.

AU - Ad'T Khaled, N.

AU - Bachert, C.

AU - Baena-Cagnani, C. E.

AU - Bouchard, J.

AU - Bunnag, C.

AU - Canonica, G. W.

AU - Carlsen, K. H.

AU - Chen, Y. -. Z.

AU - Cruz, A. A.

AU - Custovic, A.

AU - Demoly, P.

AU - Dubakiene, R.

AU - Durham, S.

AU - Fokkens, W.

AU - Howarth, P.

AU - Kemp, J.

AU - Kowalski, M. L.

AU - Kvedariene, V.

AU - Lipworth, B.

AU - Lockey, R.

AU - Lund, V.

AU - Mavale-Manuel, S.

AU - Meltzer, E. O.

AU - Mullol, J.

AU - Naclerio, R.

AU - Nekam, K.

AU - Ohta, K.

AU - Papadopoulos, N.

AU - Passalacqua, G.

AU - Pawankar, R.

AU - Popov, T.

AU - Potter, P.

AU - Price, David Brendan

AU - Scadding, G.

AU - Simons, F. E. R.

AU - Spicak, V.

AU - Valovirta, E.

AU - Wang, D. -. Y.

AU - Yawn, B.

AU - Yusuf, O.

PY - 2006/9

Y1 - 2006/9

N2 - The pharmacologic treatment of allergic rhinitis proposed by ARIA is an evidence-based and step-wise approach based on the classification of the symptoms. The ARIA workshop, held in December 1999, published a report in 2001 and new information has subsequently been published. The initial ARIA document lacked some important information on several issues. This document updates the ARIA sections on the pharmacologic and anti-IgE treatments of allergic rhinitis. Literature published between January 2000 and December 2004 has been included. Only a few studies assessing nasal and non-nasal symptoms are presented as these will be discussed in a separate document.

AB - The pharmacologic treatment of allergic rhinitis proposed by ARIA is an evidence-based and step-wise approach based on the classification of the symptoms. The ARIA workshop, held in December 1999, published a report in 2001 and new information has subsequently been published. The initial ARIA document lacked some important information on several issues. This document updates the ARIA sections on the pharmacologic and anti-IgE treatments of allergic rhinitis. Literature published between January 2000 and December 2004 has been included. Only a few studies assessing nasal and non-nasal symptoms are presented as these will be discussed in a separate document.

KW - ARIA

KW - asthma

KW - GA(2)LEN

KW - IgE

KW - pharmacotherapy

KW - rhinitis

KW - AQUEOUS NASAL SPRAY

KW - PLACEBO-CONTROLLED TRIAL

KW - QUALITY-OF-LIFE

KW - LORATADINE 10 MG

KW - INTRANASAL FLUTICASONE PROPIONATE

KW - ENVIRONMENTAL EXPOSURE UNIT

KW - RANDOMIZED CONTROLLED-TRIAL

KW - EBASTINE 20 MG

KW - LEUKOTRIENE RECEPTOR ANTAGONISTS

KW - ADRENAL AXIS FUNCTION

U2 - 10.1111/j.1398-9995.2006.01144.x

DO - 10.1111/j.1398-9995.2006.01144.x

M3 - Editorial

VL - 61

SP - 1086

EP - 1096

JO - Allergy

JF - Allergy

SN - 0105-4538

ER -